The developer of the inhaled vaccine that was approved in September (CanSino Biologics) has not submitted an application seeking the U.S. FDA's authorization to date for their Convidecia Air vaccine and it doesn't look like they have announced an intention to do so. They have some clinical trials sponsored for the vaccine, but none appear to be registered to enroll participants in the U.S.
Some have expressed skepticism over the benefit that these kinds of vaccines could offer relative to currently available vaccines in the U.S., including recently in a viewpoint co-authored by the FDA's top-ranking vaccines official Peter Marks:
"It is also not at all clear from well-controlled clinical trials that administering existing vaccines by the intranasal route (as some countries have already even approved) will provide truly meaningful benefit over the existing generation of COVID-19 vaccines. Such limitations were recently illustrated by the disappointing results with a viral-vectored vaccine administered intranasally in an early-phase clinical trial."
alexander_sn t1_j2bd43d wrote
Reply to comment by gerd50501 in Is the BF.7 mutation of Omicron less severe than variants? by Active_Bedroom_5495
The developer of the inhaled vaccine that was approved in September (CanSino Biologics) has not submitted an application seeking the U.S. FDA's authorization to date for their Convidecia Air vaccine and it doesn't look like they have announced an intention to do so. They have some clinical trials sponsored for the vaccine, but none appear to be registered to enroll participants in the U.S.
Some have expressed skepticism over the benefit that these kinds of vaccines could offer relative to currently available vaccines in the U.S., including recently in a viewpoint co-authored by the FDA's top-ranking vaccines official Peter Marks:
"It is also not at all clear from well-controlled clinical trials that administering existing vaccines by the intranasal route (as some countries have already even approved) will provide truly meaningful benefit over the existing generation of COVID-19 vaccines. Such limitations were recently illustrated by the disappointing results with a viral-vectored vaccine administered intranasally in an early-phase clinical trial."